• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

    3/25/25 6:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email

    In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental offerings, reaffirming its commitment to solving industry's toughest problems

    Partnership aims to integrate innovative new material science and disruptive technology like chairside 3D printing to optimize workflows, enhance procedural efficiency and benefit both patients and practitioners

    ST. PAUL, Minn., March 25, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership with SprintRay, a leading provider of chairside 3D dental printing, to meet the needs of dentists with in-office chairside 3D printed crowns, inlays, onlays and more. This research and development (R&D) and commercialization agreement is focused on developing and bringing to market high-quality, durable and permanent same-day restorations – with the quality patients and dentists expect from the current multi-visit laboratory fabricated procedures.

    Solventum: Group portrait of a team of three dental professionals on a dark green background.

    Solventum Dental Solutions connects leading-edge materials with data science to help dentists solve their toughest challenges with products such as Filtek™ Easy Match Universal Restorative, Filtek™ Matrix, Scotchbond™ Universal and RelyX™ Universal Cement. SprintRay offers innovative chairside end-to-end 3D printing ecosystems, which create a platform for a wide range of restorative dental applications.

    With Solventum's legacy of best-in-class material science with leading restorative materials, and SprintRay's innovative technology, the partnership aims to bring to market the first permanent chairside, 3D printed crown. Together, Solventum and SprintRay anticipate improvement in patient experience and outcomes through fewer office visits – driving practice efficiency, and ultimately, delivering the outcomes patients and providers demand.

    "Imagine a world where your dentist can create a crown that can last decades in a matter of minutes," said Karim Mansour, President, Dental Solutions, Solventum. "We believe this partnership will revolutionize the way dentists and orthodontists care for patients with in-office production, offering a simplified procedure that we anticipate will improve outcomes and experiences, reduce chair time and lower treatment costs. This collaboration allows us to integrate the latest technological advancements into our proven restorative solutions, ensuring we remain at the forefront of dental innovation to deliver unparalleled care to our patients."

    Offering cutting-edge 3D printing technology directly to dentists and orthodontists will streamline care for patients and providers, allowing the delivery of same-visit dentistry and introducing a market for permanent 3D printed crowns, inlays, onlays and more. 

    "Together, we can make a significant impact in restorative dentistry by building exceptional products for same-visit treatment," said SprintRay CEO Amir Mansouri. "Our partnership with Solventum is a key collaboration and commitment to making a difference in people's oral health as well as enabling high-quality and cost-effective dental restorations across the globe."

    The announcement of the partnership aligns with Solventum's legacy of quality material science and is one example of biasing resources towards growth while strengthening digital capabilities, two elements of Solventum's previously announced three-phased plan. As the winner of seven Dental Advisor awards in 2024, the partnership follows four new product introductions launched in 2024, including:

    • 3M™ Clarity™ Precision Grip Attachments, the first 3D printed aligner attachments
    • 3M™ Clinpro™ Clear Fluoride Treatment, a new water-based formula for smoother application and a more comfortable patient experience
    • Clarity™ Flex + Force Aligners, new proprietary multi-layer copolymer extruded in different thicknesses to best express varying degrees of movement
    • 3M™ Filtek™ Easy Match Universal Restorative features naturally adaptive opacity and offers an intuitive shade selection process to simplify direct restorative procedures

    Solventum will share more details about the strategic partnership at the International Dental Show (IDS) 2025 on March 26 in Cologne, Germany.

    About Solventum

    At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

    Forward-Looking Statements

    This news release contains forward-looking information about Solventum's financial results, estimates, and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) ; the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (6) reduction in customers' research budgets or government funding; (7) the timing and market acceptance of Solventum's new product and service offerings; (8) ongoing working relationships with certain key healthcare professionals; (9) changes in reimbursement practices of governments or private payers or other cost containment measures; (10) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (11) risks related to the highly regulated environment in which Solventum operates; (12) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights.

    Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

    Solventum Logo (PRNewsfoto/3M Healthcare US Opco  LLC)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-partners-with-sprintray-to-disrupt-the-digital-dentistry-market-with-high-quality-permanent-same-day-restorations-302411305.html

    SOURCE Solventum

    Get the next $SOLV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    7/15/2025$103.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$90.00Hold → Buy
    Argus
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    5/19/2025$87.00Neutral → Overweight
    Piper Sandler
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum Announces Pricing of Secondary Offering of Common Stock

    ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE:SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any of the proceeds from the Offering. The Offering is expected to close on or about Aug. 15, 2025, subject to customary closing conditions.

    8/13/25 10:39:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Announces Launch of Secondary Offering of Common Stock

    ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE:SOLV, ", Company", or ", Solventum", )) today announced the launch of a secondary offering (the "Offering") of 8,800,000 shares of its common stock, par value $0.01 per share, by 3M Company (the "Selling Shareholder"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any proceeds from the Offering.  Goldman Sachs & Co. LLC and BofA Securities, Inc. will act as the underwriters for the Offering. The shares of common stock are being offered pursua

    8/13/25 4:48:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports Second Quarter 2025 Financial Results

    Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"

    8/7/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 3m Co sold $646,360,000 worth of shares (8,800,000 units at $73.45), decreasing direct ownership by 26% to 25,569,190 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    8/18/25 5:02:54 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Director Cox Carrie Smith converted options into 5,148 shares (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    5/15/25 4:23:40 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Hanson Bryan C converted options into 34,315 shares and covered exercise/tax liability with 13,503 shares, increasing direct ownership by 51% to 61,605 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    5/15/25 4:23:28 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

    8/18/25 5:03:26 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    8/15/25 4:13:53 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 424B7 filed by Solventum Corporation

    424B7 - Solventum Corp (0001964738) (Filer)

    8/14/25 5:19:35 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

    Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

    1/8/25 6:30:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

    ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

    10/10/24 9:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum Reports Second Quarter 2025 Financial Results

    Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"

    8/7/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

    ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Aug. 7, 2025 Time: 3:30 p.m. CDT / 4:30 p.m. EDT Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (

    7/17/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports First Quarter 2025 Financial Results

    Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

    5/8/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Solventum upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Solventum from Equal-Weight to Overweight and set a new price target of $103.00

    7/15/25 8:30:16 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by Argus with a new price target

    Argus upgraded Solventum from Hold to Buy and set a new price target of $90.00

    7/1/25 8:13:22 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    KeyBanc Capital Markets initiated coverage on Solventum Corporation

    KeyBanc Capital Markets initiated coverage of Solventum Corporation with a rating of Sector Weight

    6/6/25 8:37:20 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care